Clinical trials: COVID-19 Drug Treatment
Quality of Life, Injection Site Reaction
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
This study is a prospective, randomized clinical trial. During this study, participants will be randomly assigned to receive quadrivalent inactivated influenza vaccine (IIV4) and mRNA COVID-19 vaccine either simultaneously or…
- Conditions
- Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
- Trial name
- NCT05028361
- Testing
- mRNA COVID-19, IIV4
- Where
- 3 sites in United States
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID 19
Inhaled Ciclesonide for Outpatients With COVID19
The CONTAIN (CiclesOnide cliNical TriAl covId-19 treatmeNt) is a randomized control study of ciclesonide vs placebo for mild covid-19 disease. The need for potential therapy for COVID-19 patients is urgent.
- Trial name
- CONTAIN (NCT04435795)
- Testing
- Ciclesonide, Ciclesonide nasal
- Where
- 3 sites in Canada
- Volunteers
- 215 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID-19
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if a high dose of Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) can reduce all-cause mortality versus SMT alone in hospitalized participants with COVID-19…
- Trial name
- NCT04480424
- Testing
- GAMUNEX-C, Standard Medical Treatment
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Grifols Therapeutics LLC
COVID-19
A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
The purpose of this study is to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for…
- Trial name
- EMPATHY (NCT04828161)
- Testing
- ensovibep
- Where
- 48 sites in United States, Hungary and 3 more
- Volunteers
- 407 people
- Sponsor
- Novartis Pharmaceuticals
Bioequivalence
Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting…
- Trial name
- Favipiravir (NCT04400682)
- Testing
- FAVIRA 200 MG Film Tablet, AVIGAN 200 MG Film Tablets
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novelfarma Ilaç San. ve Tic. Ltd. Sti.
COVID-19, Coronavirus
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting.
- Conditions
- COVID-19, Coronavirus, SARS-CoV-2
- Trial name
- PassItOn (NCT04362176)
- Testing
- pathogen reduced SARS-CoV-2 convalescent plasma
- Where
- 26 sites in United States
- Volunteers
- 974 people
- Sponsor
- Vanderbilt University Medical Center
COVID-19, SARS-CoV-2
Azithromycin for COVID-19 Treatment in Outpatients Nationwide
This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not…
- Trial name
- ACTION (NCT04332107)
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- 263 people
- Sponsor
- Thomas M. Lietman
Healthy Participants
Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on Midazolam (a cytochrome P450 [CYP]3A4 substrate) in Healthy Adult Participants.
- Trial name
- NCT05032950
- Testing
- Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Coronavirus, Coronavirus Infection
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate…
- Conditions
- Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia
- Trial name
- CYNKCOVID (NCT04365101)
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celularity Incorporated
Type 2 Diabetes
Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic
The current study was to develop a software "Line@" based health education program, providing video-based health information and communication between diabetes patients and health-care professionals.
- Trial name
- NCT04876274
- Testing
- TMU-LOVE
- Where
- Taiwan
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University
COVID-19
Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir. Subjects will be assessed daily while hospitalized.
- Trial name
- NCT04640168
- Testing
- Baricitinib, Dexamethasone, Remdesivir
- Where
- 72 sites in United States, Japan and 3 more
- Volunteers
- 1,010 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
COVID-19 Treatment Cascade Optimization Study
This study tests an adaptation of the HIV Continuum of Prevention, Care, and Treatment Framework (CoPCT) for use in tracking COVID-19 testing and follow-up in a medically and socially vulnerable population.
- Trial name
- NCT05305443
- Testing
- Navigation Services, Brief Counseling, Critical Dialogue
- Where
- United States
- Volunteers
- 554 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Urbana-Champaign
COVID-19-Induced Parosmia
Stellate Ganglion Block for COVID-induced Parosmia
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected.
- Trial name
- SGB (NCT06253806)
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
COVID-19
Treatment of COVID-19 Patients With Anti-interleukin Drugs
The purpose of this study is to test the safety and effectiveness of individually or simultaneously blocking IL-6 and IL-1 versus standard of care on blood oxygenation and systemic cytokine release syndrome in patients with…
- Trial name
- COV-AID (NCT04330638)
- Testing
- Usual Care, Anakinra, Siltuximab
- Where
- 15 sites in Belgium
- Volunteers
- 342 people
- Sponsor
- University Hospital, Ghent
Viral Respiratory Tract Infection
Safety and Tolerability of Single and Multiple Doses of Neumifil
This is a Phase 1, single-centre, randomised, placebo-controlled first in human study in healthy subjects. The study will assess the safety and tolerability of single-ascending (Part A) and multiple-ascending (Part B) doses of…
- Trial name
- NCT05093530
- Testing
- Neumifil
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pneumagen Ltd.
COVID-19, SARS-CoV-2 Infection
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT04924660)
- Testing
- TXA127, TRV027, Fostamatinib
- Where
- 51 sites in United States
- Volunteers
- 1,060 people
- Sponsor
- Sean Collins
Healthy Participants
PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants
This is a drug-drug interaction study to assess the effects of PF-07321332/ritonavir and ritonavir on the Pharmacokinetic (PK) of dabigatran in healthy volunteers. PK will be evaluated for PF-07321332 and ritonavir.
- Trial name
- NCT05064800
- Testing
- Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Coronavirus Disease 2019 (COVID-19)
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
This study evaluates the efficacy and safety of efprezimod alfa in hospitalized adult participants who are diagnosed with coronavirus disease 2019 (COVID-19) and receiving oxygen support.
- Trial name
- SAC-COVID (NCT04317040)
- Testing
- Efprezimod alfa
- Where
- 10 sites in United States
- Volunteers
- 234 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
COVID-19
Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
Introduction: Corona Virus induced disease - 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now.
- Trial name
- NCT05502081
- Testing
- Casirivimab and Imdevimab Drug Combination, Remdesivir, Favipiravir
- Where
- Egypt
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Mansoura University Hospital
COVID-19
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound.
- Trial name
- NCT05567952
- Testing
- nirmatrelvir, ritonavir
- Where
- 84 sites in United States, Canada and 3 more
- Volunteers
- 436 people
- Sponsor
- Pfizer